BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1621 related articles for article (PubMed ID: 16572427)

  • 21. Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients.
    Hoebe EK; Hutajulu SH; van Beek J; Stevens SJ; Paramita DK; Greijer AE; Middeldorp JM
    Clin Vaccine Immunol; 2011 Feb; 18(2):298-304. PubMed ID: 21123521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
    Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma.
    Tong JH; Tsang RK; Lo KW; Woo JK; Kwong J; Chan MW; Chang AR; van Hasselt CA; Huang DP; To KF
    Clin Cancer Res; 2002 Aug; 8(8):2612-9. PubMed ID: 12171892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
    Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
    Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
    Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
    BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region.
    Pramanik R; Arora S; Sharma P; Biswas A; Nayak B; Thakar A; Sharma A; Ghose S
    J Med Virol; 2022 Feb; 94(2):720-728. PubMed ID: 34750844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
    Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
    Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
    Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
    Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis.
    Feng P; Ren EC; Liu D; Chan SH; Hu H
    J Gen Virol; 2000 Oct; 81(Pt 10):2417-2423. PubMed ID: 10993929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nasopharyngeal brushing: a convenient and feasible sampling method for nucleic acid-based nasopharyngeal carcinoma research.
    Zhang PF; Zheng XH; Li XZ; Tian T; Zhang SD; Hu YZ; Jia WH
    Cancer Commun (Lond); 2018 Apr; 38(1):8. PubMed ID: 29764493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
    Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
    Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
    J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of Epstein-Barr virus in nasopharynx tissue and desquamatine cell for diagnosis of nasopharyngeal carcinoma].
    Sun Z; Xiao C; Jiang W; Feng X; Liu Y
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Feb; 20(4):153-4. PubMed ID: 16711437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nasopharyngeal Epstein-Barr virus DNA loads in high-risk nasopharyngeal carcinoma families: Familial aggregation and host heritability.
    Zheng MQ; Wang TM; Liao Y; Xue WQ; He YQ; Wu ZY; Yang DW; Li DH; Deng CM; Jia YJ; Yuan LL; Zhang WL; Luo LT; Tong XT; Wu YX; Zhou T; Li XZ; Tang LL; Zhang JB; Xia YF; Mu J; Jia WH
    J Med Virol; 2020 Dec; 92(12):3717-3725. PubMed ID: 32558959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
    Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
    Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
    Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
    Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus.
    Fan H; Nicholls J; Chua D; Chan KH; Sham J; Lee S; Gulley ML
    Int J Cancer; 2004 Dec; 112(6):1036-41. PubMed ID: 15386346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 82.